

Date: 18th February, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
BSE Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir / Madam,

Sub: Completion of United States Food and Drug Administration inspection at Alembic Pharmaceuticals Limited' Injectable Facility (F-3) at Karakhadi

The Company hereby informs that the United States Food and Drug Administration (USFDA) conducted an unannounced cGMP inspection at its Injectable Facility (F-3) located at Karakhadi from 9th February, 2026 to 18th February, 2026.

The inspection has been completed with two observations. None of the observations are related to data integrity.

The Company will respond to the observations within the stipulated time.

The Company continues to remain committed to highest quality standards and compliance.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123